Safety of Nintedanib in Patients with Idiopathic Pulmonary Fibrosis: Global Pharmacovigilance Data

Clicks: 240
ID: 117531
2020
Free PDF
Article Quality & Performance Metrics
Overall Quality
Not rated
Combines reader engagement with the AI quality analysis. This article has not been analysed, so there is no overall score — reader engagement is measured and shown alongside.
AI Quality Assessment
Not analyzed
Readership in this journal
Steady

Ranked #14 of 29 articles by views in Advances in therapy

Most read Least read

Bar heights use a square-root scale.

Mint this article as an NFT
Not yet minted

Create a permanent, verifiable on-chain record of this article on the Scimatic Network. The NFT is held in your Journament account, and you can withdraw it to your own wallet at any time.

5 SUSD one-off · no wallet required
Sign in to mint
Abstract
On the basis of pharmacovigilance data collected over 4 years, the safety profile of nintedanib in patients with IPF was consistent with that observed in clinical trials and described in the product label, with no new safety concerns observed.
Reference Key
ja2020advancessafety Use this key to autocite in the manuscript while using SciMatic Manuscript Manager or Thesis Manager
Authors Lasky JA;Criner GJ;Lazarus HM;Kohlbrenner V;Bender S;Richeldi L;;
Journal Advances in therapy
Year 2020
DOI
DOI not found
URL
http://www.ncbi.nlm.nih.gov/pubmed/32767182
Keywords
National Center for Biotechnology Information NCBI NLM MEDLINE pubmed abstract nih national institutes of health national library of medicine pmid:32767182 doi:10.1007/s12325-020-01452-5 joseph a lasky gerard j criner luca richeldi

Citations

No citations found. To add a citation, contact the admin at info@scimatic.org

Comments

No comments yet. Be the first to comment on this article.